Legend came to an agreement with the depository, JPMorgan Chase, forbidding the proxy voting. GenScript, a company that offers biotech research instruments and services, has recently come under the gaze of the BioSecure Act, the effort by the US Congress to prevent China's biopharma companies from stealing IP. Although it was founded in the US, GenScript has contract development manufacturing organization (CDMO) facilities in China. The chief target of the proposed BioSecure Act is WuXi Apptec. GenScript said it has not been targeted by the BioSecure Act. In one more wrinkle, Legend has been rumored to be a takeover target by an unknown suitor as it gears up for a NASDAQ IPO. Legend said the GenScript split was not caused by the BioSecure Act, but instead was driven by its interest in "good corporate governance."